Syntara Limited has released a press release.
Quarterly Appendix 4C Cash Flow Report
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Syntara
- Quarterly Shareholder Report
- New positive interim data in Phase 2 study of SNT-5505
- SNT-5505 awarded US FDA Fast Track designation
- Quarterly Activities Report
- Acceleration of skin scarring program
Later from Syntara
- Suspension from Quotation
- Reinstatement to Quotation
- Guidance from FDA on amsulostat clinical progression
- Preliminary Final Report
- Positive top-line Phase 2a data confirms competitive profile
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara